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Introduction {#tca13244-sec-0005}
============

Esophageal cancer is one of the leading causes of cancer‐related mortality worldwide.[1](#tca13244-bib-0001){ref-type="ref"} Although adenocarcinoma is one of the predominant histological subtypes in the western world, squamous cell carcinoma is most prevalent in Asia.[1](#tca13244-bib-0001){ref-type="ref"}, [2](#tca13244-bib-0002){ref-type="ref"}

For locally advanced esophageal squamous cell carcinoma (LA‐ESqCC), definitive concurrent chemoradiotherapy (dCCRT) is one of the most common treatment strategies.[3](#tca13244-bib-0003){ref-type="ref"}, [4](#tca13244-bib-0004){ref-type="ref"}, [5](#tca13244-bib-0005){ref-type="ref"}

Image‐guided radiotherapy (IGRT) is an advanced form of ancillary radiotherapy technique advocated in reviews and textbooks.[6](#tca13244-bib-0006){ref-type="ref"}, [7](#tca13244-bib-0007){ref-type="ref"}, [8](#tca13244-bib-0008){ref-type="ref"} IGRT employs imaging (usually x‐rays) before and/or during the delivery of radiotherapy to improve the precision and accuracy of treatment delivery.[7](#tca13244-bib-0007){ref-type="ref"} Conceptually, the improvement of radiotherapy delivery accuracy may lead to improved outcome, as reported in our previous nonrandomized study utilizing the Taiwan Cancer Registry (TCR).[9](#tca13244-bib-0009){ref-type="ref"}

However, a recent randomized controlled trial (RCT) in 2018 by de Crevoisier *et al*. for prostate cancer patients treated with radiotherapy via either IGRT or routine care (no daily IGRT) reported a statistically significantly worse overall survival for those treated with IGRT, although side‐effects and disease control were improved.[10](#tca13244-bib-0010){ref-type="ref"} This raised the concern regarding the effectiveness of IGRT for other scenarios such as dCCRT for LA‐ESqCC.

Since 2011, additional prognostic factors, such as body mass index (BMI), use of alcohol, betel nuts or smoking, and use of positron emission tomography (PET), were prospectively collected in the TCR. Because these potential confounders were not adjusted in our previous study due to data limitation at that time, we aimed to investigate the effectiveness of IGRT for LA‐ESqCC patients treated with dCCRT in this updated analysis with consideration of the above potential confounders.

Methods {#tca13244-sec-0006}
=======

Data source {#tca13244-sec-0007}
-----------

In our retrospective cohort study, the data is derived from the Health and Welfare Data Science Center (HWDC) database including the Taiwan Cancer Registry (TCR), death registration and reimbursement data for the whole population of Taiwan provided by the Bureau of National Health Insurance (NHI). All the above data were included in the HWDC with personal identifiers removed. The TCR is a high‐quality database that provides complete information such as patient/disease/treatment characteristics and prognostic factor details.[11](#tca13244-bib-0011){ref-type="ref"} This study was approved by the Research Ethics Committee, National Health Research Institutes (CMUH104‐REC‐003).

Study population and study design {#tca13244-sec-0008}
---------------------------------

The main study flow chart designed to conform to the STROBE statement[12](#tca13244-bib-0012){ref-type="ref"} is depicted in Fig [1](#tca13244-fig-0001){ref-type="fig"}. The study population consisted of nonoperated locally advanced esophageal squamous cell carcinoma (LA‐ESqCC) adult (age \> = 18) patients diagnosed from 2011--2015 who received concurrent systemic therapy and external beam radiotherapy 50--70 Gy using conventional fractionation via image‐guided radiotherapy (IGRT) or non‐IGRT. We excluded patients with other cancer(s) and determined the explanatory variable of interest (IGRT vs. non‐IGRT), the primary outcome of interest (overall survival \[OS\]) and other supplementary outcomes (complete clinical response \[cCR\], incidence of esophageal cancer mortality \[IECM\], other cancer mortality \[IOCM\] and cardiovascular mortality \[ICVM\]) based on the TCR or determined via the death registry. The date of diagnosis in the TCR was defined as the index date and OS was calculated from the date of diagnosis to the date of death or 31 December 2017 (censoring date of the death registry). The related covariables were collected based on our experiences in clinical care and TCR studies[9](#tca13244-bib-0009){ref-type="ref"}, [13](#tca13244-bib-0013){ref-type="ref"} to adjust for potential nonrandomized treatment selection (see below). We estimated the propensity scores (PS) via the above covariables to construct a PS‐matched sample and then evaluated the effectiveness of IGRT.

![STROBE study flowchart and the number of individuals at each stage of the study. ^a^We only included those treated (class 1--2) by any single institution to ensure data consistency. ^b^The Seventh American Joint Committee on Cancer staging clinical stage II--III. ^c^Without missing information in the TCR and death registry regarding survival status, cause of death, and clinical response.](TCA-11-113-g001){#tca13244-fig-0001}

Other explanatory covariables {#tca13244-sec-0009}
-----------------------------

Patient demographics (age, gender, residency), patient characteristics (comorbidity, drinking, betel nut chewing, smoking, body mass index \[BMI\]), disease characteristics (T‐stage, N‐stage), treatment characteristics (radiotherapy \[RT\] delivery), and prognostic factor (use of PET) were included in the primary analysis. Three "variables of ambiguous status," which were "perhaps slightly affected by the treatment, but plausibly standing in as a surrogate for an important covariable that was not measured" were included in the sensitivity analysis (SA)[14](#tca13244-bib-0014){ref-type="ref"}: the use of peri‐CCRT (ie, induction or consolidative) systemic therapy, radiotherapy break, and radiotherapy dose (see Statistical and Sensitivity Analysis). The covariables were defined as follows. Age was classified as at least 65 years old or not. Patient residency region was classified as northern Taiwan or elsewhere. Comorbidity was classified as with or without via Carlson comorbidity score. The drinking, betel nut chewing, smoking, and use of PET covariables were classified as yes or no. Clinical stage was classified as T1--T2 versus. T3--T4 for T‐stage and negative versus positive for N‐stage. RT delivery was classified as 3D conformal radiotherapy (3DCRT) or intensity‐modulated radiotherapy (IMRT). Peri‐CCRT systemic therapy was classified as with or without. RT break was defined as more than one week or not.

Statistical and sensitivity analysis {#tca13244-sec-0010}
------------------------------------

In the primary analysis (PA), we used the propensity‐score (PS) method as advocated in the literature to balance the measured potential confounders.[15](#tca13244-bib-0015){ref-type="ref"}, [16](#tca13244-bib-0016){ref-type="ref"}, [17](#tca13244-bib-0017){ref-type="ref"}, [18](#tca13244-bib-0018){ref-type="ref"} We evaluate the probability of receiving IGRT (vs. non‐IGRT) via a logistic regression model based on all the above covariables, and then used the logit of the probability as the PS. The standardized difference (SDif) was used to assess the balance of covariates between 1:1 PS‐matched groups.[19](#tca13244-bib-0019){ref-type="ref"}, [20](#tca13244-bib-0020){ref-type="ref"} We compared the hazard ratio (HR) of death between IGRT and non‐IGRT matched groups during the entire follow‐up period via a robust variance estimator.[16](#tca13244-bib-0016){ref-type="ref"} As suggested in the recent literature,[21](#tca13244-bib-0021){ref-type="ref"} we also used the E‐factor to evaluate the impact of potential unmeasured confounding factor(s) on OS. Binary outcomes (cCR) within the matched pairs were compared using McNemar\'s test. We adopted the subdistribution HR via the clustered Fine‐Gray model to evaluate IECM, IOCM and ICVM.[22](#tca13244-bib-0022){ref-type="ref"} In the sensitivity analysis (SA), we reanalyzed what we did in the PA when we considered an additional three covariables (peri‐CCRT systemic therapy, RT break, and RT dose).

We performed the statistical analyses using the software SAS 9.4 (SAS Institute, Cary, NC) and R (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria) version 3.5.3.

Results {#tca13244-sec-0011}
=======

Identification of the study population used in the primary analysis {#tca13244-sec-0012}
-------------------------------------------------------------------

As shown in Fig [1](#tca13244-fig-0001){ref-type="fig"}, the identified initial study population consisted of 1632 nonoperated esophageal LA‐ESqCC cancer adult patients who received IGRT or non‐IGRT in 2011--2015. A total of 590 eligible PS‐matched patients were used as our primary study population and divided into two groups (IGRT group \[*n* = 295\] vs. non‐IGRT group \[*n* = 295\]). Radiotherapy was predominantly delivered via IMRT. The patient characteristics are described in Table [1](#tca13244-tbl-0001){ref-type="table"}. All covariables after PS‐matching were well balanced with small standardized differences (\<0.1) although some could not be well balanced before PS‐matching.

###### 

Patient characteristics of the study population in the primary analysis

                                                                                        Unmatched population                                                                                    Matched study population                                                                                                                                                                                                                                                                                                                                  
  ------------------- --------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ------------------------------------------------------------ -------------------------------------------- --------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ---------------------------------------------
                                                                     Number or mean (sd)[†](#tca13244-note-0002){ref-type="fn"}   (%)[†](#tca13244-note-0002){ref-type="fn"}   Number or mean (sd)[†](#tca13244-note-0002){ref-type="fn"}   (%)[†](#tca13244-note-0002){ref-type="fn"}   SDif[†](#tca13244-note-0002){ref-type="fn"}   Number or mean (sd)[†](#tca13244-note-0002){ref-type="fn"}   (%)[†](#tca13244-note-0002){ref-type="fn"}   Number or mean (sd)[†](#tca13244-note-0002){ref-type="fn"}   (%)[†](#tca13244-note-0002){ref-type="fn"}   SDif[†](#tca13244-note-0002){ref-type="fn"}
  Age                                     \< 65                                                 219                                                 \(74\)                                                590                                                 \(78\)                                        0.096                                                 219                                                 \(74\)                                                222                                                 \(75\)                                        0.023
                                          ≥ 65                                                   78                                                 \(26\)                                                168                                                 \(22\)                                                                                               76                                                 \(26\)                                                 73                                                 \(25\)                    
  Gender                                 Female                                                  13                                                 \(4\)                                                  45                                                 \(6\)                                         0.071                                                  13                                                 \(4\)                                                  12                                                 \(4\)                                         0.017
                                          Male                                                  284                                                 \(96\)                                                713                                                 \(94\)                                                                                              282                                                 \(96\)                                                283                                                 \(96\)                    
  Residency                             Non‐north                                               214                                                 \(72\)                                                518                                                 \(68\)                                        0.081                                                 212                                                 \(72\)                                                217                                                 \(74\)                                        0.038
                                          North                                                  83                                                 \(28\)                                                240                                                 \(32\)                                                                                               83                                                 \(28\)                                                 78                                                 \(26\)                    
  Comorbidity                            Without                                                179                                                 \(60\)                                                466                                                 \(61\)                                        0.025                                                 178                                                 \(60\)                                                178                                                 \(60\)                                          0
                       With[‡](#tca13244-note-0003){ref-type="fn"}                              118                                                 \(40\)                                                292                                                 \(39\)                                                                                              117                                                 \(40\)                                                117                                                 \(40\)                    
  T‐stage                                 T1‐T2                                                  51                                                 \(17\)                                                 83                                                 \(11\)                                        0.180                                                  49                                                 \(17\)                                                 45                                                 \(15\)                                        0.037
                                          T3‐T4                                                 246                                                 \(83\)                                                675                                                 \(89\)                                                                                              246                                                 \(83\)                                                250                                                 \(85\)                    
  N‐stage                               Negative                                                 19                                                 \(6\)                                                  82                                                 \(11\)                                        0.158                                                  19                                                 \(6\)                                                  18                                                 \(6\)                                         0.014
                                        Positive                                                278                                                 \(94\)                                                676                                                 \(89\)                                                                                              276                                                 \(94\)                                                277                                                 \(94\)                    
  RT delivery                             3DCRT                               [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}                        0.241                               [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}                          0
                                          IMRT                                [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}                                                            [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}              [§](#tca13244-note-0004){ref-type="fn"}    
  Use of PET                               No                                                    69                                                 \(23\)                                                198                                                 \(26\)                                        0.067                                                  69                                                 \(23\)                                                 67                                                 \(23\)                                        0.016
                                           Yes                                                  228                                                 \(77\)                                                560                                                 \(74\)                                                                                              226                                                 \(77\)                                                228                                                 \(77\)                    
  Drinking                                 No                                                    42                                                 \(14\)                                                112                                                 \(15\)                                        0.018                                                  41                                                 \(14\)                                                 40                                                 \(14\)                                        0.010
                                           Yes                                                  255                                                 \(86\)                                                646                                                 \(85\)                                                                                              254                                                 \(86\)                                                255                                                 \(86\)                    
  Betel nut chewing                        No                                                   151                                                 \(51\)                                                335                                                 \(44\)                                        0.133                                                 149                                                 \(51\)                                                148                                                 \(50\)                                        0.007
                                           Yes                                                  146                                                 \(49\)                                                423                                                 \(56\)                                                                                              146                                                 \(49\)                                                147                                                 \(50\)                    
  Smoking                                  No                                                    44                                                 \(15\)                                                 99                                                 \(13\)                                        0.051                                                  43                                                 \(15\)                                                 42                                                 \(14\)                                        0.010
                                           Yes                                                  253                                                 \(85\)                                                659                                                 \(87\)                                                                                              252                                                 \(85\)                                                253                                                 \(86\)                    
  BMI                                                                                       22.01 (3.36)                                                                                              21.47 (3.61)                                                                                          0.154                                             22.00 (3.37)                                                                                              22.06 (3.82)                                                                                          0.016

Rounded.

Carlson comorbidity score ≥ 1.

The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤2).

3DCRT, 3D conformal radiotherapy; BMI, body mass index; IGRT, image‐guided radiotherapy; IMRT, intensity‐modulated radiotherapy; PET, positron emission tomography; RT, radiotherapy; sd, standard deviation; SDif, standardized difference.

Primary analysis {#tca13244-sec-0013}
----------------

After a median follow‐up of 16 months (range 2--84 months), death was observed for 218 patients in the IGRT group and for 227 in the non‐IGRT group. The HR of death when IGRT was compared to non‐IGRT was 0.92 (95% confidence interval \[95% CI\] 0.77--1.10, *P* = 0.35). The observed HR 0.92 for OS could be explained by an unmeasured confounder associated with the selection of treatment (IGRT or non‐IGRT) and survival by a risk ratio of 1.31 (E‐value) fold each, but weaker confounding factors could not do so. The five‐year OS rates for IGRT versus non‐IGRT were 19% and 22%. Figure [2](#tca13244-fig-0002){ref-type="fig"} shows the Kaplan‐Meier survival curve for OS. The results of the HR for IECM (HR = 0.92, *P* = 0.37), IOCM (HR = 1.1, *P* = 0.8) and ICVM (HR = 1, *P* = 1) were also not significantly different. The cCR rates were 24% versus 22% for IGRT versus non‐IGRT groups (*P* = 0.63).

![Kaplan‐Meier overall survival curve (in years) in the primary analysis. (![](TCA-11-113-g003.jpg "image")) non‐IGRT and (![](TCA-11-113-g004.jpg "image")) IGRT.](TCA-11-113-g002){#tca13244-fig-0002}

Sensitivity analysis (SA) {#tca13244-sec-0014}
-------------------------

When considering an additional three covariables (peri‐CCRT systemic therapy, RT break, and RT dose), we were still able to construct balanced study populations after PS‐matching (Table [2](#tca13244-tbl-0002){ref-type="table"}). The HR for death when IGRT was compared with non‐IGRT was similar as in the PA (HR = 0.93; 95% CI 0.77--1.12; *P* value = 0.42). The five‐year OS rates for IGRT versus non‐IGRT were 19% and 20%. There was also no statistically significant difference for the results of the other outcomes (HR = 0.95, *P* = 0.62 for IECM; HR = 0.99, *P* = 0.98 for IOCM; HR = 0.66, *P* = 0.65 for ICVM) and the distribution of the cCR rates (24% vs. 27% for IGRT vs. non‐IGRT groups, *P* = 0.41\].

###### 

Patient characteristics of the study population in the sensitivity analysis

                                                                                                   IGRT (*n* = 295)                                                                                        non‐IGRT (*n* = 295)                                                                  
  ---------------------------- --------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ---------------------------------------------
                                                                              Number or mean (sd)[†](#tca13244-note-0006){ref-type="fn"}   (%)[†](#tca13244-note-0006){ref-type="fn"}   Number or mean (sd)[†](#tca13244-note-0006){ref-type="fn"}   (%)[†](#tca13244-note-0006){ref-type="fn"}   SDif[†](#tca13244-note-0006){ref-type="fn"}
  Age                                              \< 65                                                 219                                                 \(74\)                                                223                                                 \(76\)                                        0.031
                                                   ≥ 65                                                   76                                                 \(26\)                                                 72                                                 \(24\)                    
  Gender                                          Female                                                  13                                                 \(4\)                                                  9                                                  \(3\)                                         0.072
                                                   Male                                                  282                                                 \(96\)                                                286                                                 \(97\)                    
  Residency                                      Non‐north                                               212                                                 \(72\)                                                209                                                 \(71\)                                        0.022
                                                   North                                                  83                                                 \(28\)                                                 86                                                 \(29\)                    
  Comorbidity                                     Without                                                178                                                 \(60\)                                                178                                                 \(60\)                                          0
                                With[‡](#tca13244-note-0007){ref-type="fn"}                              117                                                 \(40\)                                                117                                                 \(40\)                    
  T‐stage                                          T1‐T2                                                  49                                                 \(17\)                                                 47                                                 \(16\)                                        0.018
                                                   T3‐T4                                                 246                                                 \(83\)                                                248                                                 \(84\)                    
  N‐stage                                        Negative                                                 19                                                 \(6\)                                                  16                                                 \(5\)                                         0.043
                                                 Positive                                                276                                                 \(94\)                                                279                                                 \(95\)                    
  RT delivery                                      3DCRT                               [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}                          0
                                                   IMRT                                [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}              [§](#tca13244-note-0008){ref-type="fn"}    
  Use of PET                                        No                                                    69                                                 \(23\)                                                 63                                                 \(21\)                                        0.049
                                                    Yes                                                  226                                                 \(77\)                                                232                                                 \(79\)                    
  Drinking                                          No                                                    41                                                 \(14\)                                                 37                                                 \(13\)                                        0.040
                                                    Yes                                                  254                                                 \(86\)                                                258                                                 \(87\)                    
  Betel nut chewing                                 No                                                   149                                                 \(51\)                                                147                                                 \(50\)                                        0.014
                                                    Yes                                                  146                                                 \(49\)                                                148                                                 \(50\)                    
  Smoking                                           No                                                    43                                                 \(15\)                                                 41                                                 \(14\)                                        0.019
                                                    Yes                                                  252                                                 \(85\)                                                254                                                 \(86\)                    
  BMI                                                                                                22.00 (3.37)                                                                                              21.97 (3.69)                                                                                          0.007
  Peri‐CCRT systemic therapy                      Without                                                206                                                 \(70\)                                                207                                                 \(70\)                                        0.007
                                                   With                                                   89                                                 \(30\)                                                 88                                                 \(30\)                    
  RT break                                        ≤1 week                                                205                                                 \(69\)                                                209                                                 \(71\)                                        0.030
                                                 \>1 week                                                 90                                                 \(31\)                                                 86                                                 \(29\)                    
  RT dose (Gy)                                                                                       57.75 (6.67)                                                                                              57.91 (6.54)                                                                                          0.024

Rounded.

Carlson comorbidity score ≥ 1.

The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤2).

3DCRT, 3D conformal radiotherapy; BMI, body mass index; CCRT, concurrent chemoradiotherapy; IGRT, image‐guided radiotherapy; IMRT, intensity‐modulated radiotherapy; PET, positron emission tomography; RT, radiotherapy; sd, standard deviation; SDif, standardized difference.

Discussion {#tca13244-sec-0015}
==========

In this updated nonrandomized study using real‐world data with additional potential confounders, we found that the OS of LA‐ESqCC patients treated with dCCRT was not statistically different between those treated with IGRT versus those without IGRT, although the hazard ratio was less than unity (ie, in favor of IGRT).

From the viewpoint of evidence‐based medicine, our finding was not of the highest level of evidence[23](#tca13244-bib-0023){ref-type="ref"}, [24](#tca13244-bib-0024){ref-type="ref"} and interpretation must therefore be cautious due to the nonrandomized study design.[24](#tca13244-bib-0024){ref-type="ref"} However, when we searched the clinical trial registry (<https://clinicaltrials.gov/>) in August 2019 using the keywords "(image‐guided radiation therapy) OR (image‐guided radiotherapy) OR (IGRT) \| Phase 2, 3, Not Applicable", we found no RCT regarding IGRT for LA‐ESqCC patients treated with dCCRT. Therefore, our study provided reasonable tentative evidence that there is a lack of RCT as suggested in the literature.[24](#tca13244-bib-0024){ref-type="ref"}

We searched for relevant studies by searching PubMed in August 2019 using the following keywords "((IGRT) OR (Image‐guided Radiation Therapy) OR ((image\*) AND (guid\*) AND ((radiotherapy) OR (radiation therapy)))) AND survival AND (esophageal cancer)". We found no relevant study except our previous one[9](#tca13244-bib-0009){ref-type="ref"} and another known single arm study.[24](#tca13244-bib-0024){ref-type="ref"} In our previous study, without consideration of the additional covariables as mentioned in the Introduction, we found OS was improved by IGRT with HR 0.82 in the primary analysis but the results were not robust in sensitivity analyses. When additional "variables of ambiguous status" were considered in the propensity score model, the HR was 0.95 (*P* = 0.5). In the present study, the HR was insignificantly in favor of IGRT in both the primary or sensitivity analysis. The inclusion of the additional covariables only available in the current study may at least partly explain the differences between our previous and the current study. However, the observed HR for death was less than unity (ie, still in favor of IGRT), in contrast to the HR 2.12 \[*P* = 0.042\] observed in the RCT for prostate cancer.[10](#tca13244-bib-0010){ref-type="ref"}

Our updated analysis was inspired by the unexpected results in the RCT for prostate cancer[10](#tca13244-bib-0010){ref-type="ref"} which deserved further discussion. Please note that overall survival was the secondary but not the primary outcome of the prostate RCT, in which recurrence‐free survival (primary outcome) was not different between the groups. Furthermore, higher incidence of other cancer (HR 2.28) and cardiovascular mortality (6/236 vs. 1/234) was observed in the post‐hoc analyses of this prostate study, which were all possible radiotherapy sequelae. However, the interpretation of secondary outcomes and post‐hoc analysis should be cautious but not conclusive, and similar incidences of other cancer mortality and cardiovascular mortality were observed in our study.

There were several limitations in this study. First, potential unmeasured confounders are always a limitation of a nonrandomized study as seen previously[9](#tca13244-bib-0009){ref-type="ref"} and the current study in which the treatment selection was not randomized and the reason for IGRT (vs. non‐IGRT) could not be ascertained in TCR. Although we had included additional covariables in the current study, there were still possible unmeasured confounders. For example, taxane has been used in modern RCT with excellent results,[25](#tca13244-bib-0025){ref-type="ref"} but this systemic therapy detail was not available in our study due to data limitation. Also, the detail of planning target volume (PTV) margin was not available in TCR. In addition, accessibility (IGRT may not be available in some institutes) or treatment era (more recent patients may have had a greater chance to be treated with IGRT) issues may be possible because IGRT is a relatively recent technology, although the item "IGRT" was coded in TCR since the establishment of modern TCR in year 2007. So patients treated with IGRT may have been those who had access to more modern technology and therefore a better prognosis. Therefore, we reported E‐value to quantify the potential impact of unmeasured confounder(s) as suggested in the literature. Second, the impact of novel modalities such as carbon ions[26](#tca13244-bib-0026){ref-type="ref"} or immune therapy[27](#tca13244-bib-0027){ref-type="ref"} was not considered in this study. Third, other endpoints such as recurrence‐free survival as used in the prostate cancer IGRT trial[10](#tca13244-bib-0010){ref-type="ref"} or side effects might be more relevant to the effect of IGRT. However, these endpoints could not be reliably obtained from our data sets to our knowledge. Finally, the intervention (IGRT) in our study was not homogenous. To our knowledge, several different forms of IGRT are available in Taiwan, including, but not limited to, cone beam computed tomography, kV imaging, and mV imaging, which could not be differentiated in the TCR. However, it is unclear whether these various technologies lead to different clinical benefits or not.[6](#tca13244-bib-0006){ref-type="ref"}

In conclusion, in this updated nonrandomized study using real‐world data with additional potential confounders, we found that the OS of LA‐ESqCC patients treated with dCCRT was not statistically different between those treated with IGRT versus those without IGRT, although the hazard ratio was less than unity (ie, in favor of IGRT). The results should be interpreted with caution given the nonrandomized design of the study. RCTs are needed to clarify this finding.
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